Aptevo Therapeutics (APVO) director nets 400 common shares from RSU vesting
Rhea-AI Filing Summary
Aptevo Therapeutics Inc. director John Niederhuber reported the vesting and conversion of 400 Restricted Stock Units into 400 shares of common stock on August 6, 2026. The RSUs converted on a one-for-one basis into common stock. The related footnote states that on August 6, 2025, he was granted 7,200 (400 post-split) RSUs that vest on the first anniversary of the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 400 shares
Net Buy
2 txns
Insider
Niederhuber John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit F1, F2 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 400 | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct);
Common Stock — 400 shares (Direct)
Footnotes (2)
- F1. Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
- F2. On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Key Figures
RSUs converted: 400 RSUs
Common shares acquired: 400 shares
Common shares held after transaction: 400 shares
+2 more
5 metrics
RSUs converted
400 RSUs
Restricted Stock Units converting into common stock on August 6, 2026
Common shares acquired
400 shares
Common stock received upon RSU conversion on August 6, 2026
Common shares held after transaction
400 shares
Direct common stock ownership by John Niederhuber after reported transactions
Original RSU grant
7,200 RSUs (400 post-split)
Grant to John Niederhuber on August 6, 2025, vesting after one year
RSUs remaining from this grant
0 RSUs
Total shares following transaction for the RSU derivative position
Key Terms
Restricted Stock Unit, RSUs, derivative exercise/conversion, par value
4 terms
Restricted Stock Unit financial
"Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSUs financial
"the reporting person was granted 7,200 (400 post-split) RSUs, vesting"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
par value financial
"common stock, $0.001 par value per share, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Aptevo Therapeutics (APVO) report for John Niederhuber?
Aptevo Therapeutics reported that director John Niederhuber had 400 RSUs convert into 400 shares of common stock on August 6, 2026, reflecting a vesting and derivative exercise rather than an open-market trade.
How many Aptevo Therapeutics (APVO) RSUs did John Niederhuber have convert to common stock?
John Niederhuber had 400 Restricted Stock Units convert into 400 shares of common stock. The RSUs convert on a one-for-one basis into common stock with a $0.001 par value per share, as disclosed in the footnote.
What is John Niederhuber’s common stock holding in Aptevo Therapeutics (APVO) after this Form 4?
After the reported transactions, John Niederhuber directly holds 400 shares of Aptevo Therapeutics common stock. The RSU position associated with this grant is shown as fully converted, with 0 RSUs remaining from that award.
Were John Niederhuber’s Aptevo Therapeutics (APVO) RSUs part of a prior grant?
Yes. A footnote states that on August 6, 2025, John Niederhuber was granted 7,200 RSUs (equivalent to 400 post-split RSUs), vesting on the first anniversary of the grant date, which aligns with the August 6, 2026 conversion.